Evaluation of apoptosis stimulating protein of TP53-1 (ASPP1/PPP1R13B) to predict therapy resistance and overall survival in acute myeloid leukemia (AML)

Evaluation of apoptosis stimulating protein of TP53-1 (ASPP1/PPP1R13B) to predict therapy resistance and overall survival in acute myeloid leukemia (AML)

Abstract ASPP1 (PPP1R13B) belongs to a family of p53-binding proteins and enhances apoptosis by stimulation of p53-transactivation of selected proapoptotic target genes. It is preferentially expressed in hematopoietic stem cells (HSC) and together with p53 preserves the genomic integrity of the HSC...

Full description

Bibliographic Details
Main Authors:	Marcus M. Schittenhelm, Max Kaiser, Balázs Győrffy, Kerstin M. Kampa-Schittenhelm
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-01-01
Series:	Cell Death and Disease
Online Access:	https://doi.org/10.1038/s41419-023-06372-0

Similar Items

High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML)
by: Mihada Bajrami Saipi, et al.
Published: (2024-11-01)

Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS)
by: Vasileia Tsintari, et al.
Published: (2022-07-01)

Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma
by: Johannes Kliebhan, et al.
Published: (2022-10-01)

ASPP1 and ASPP2: common activators of p53 family members.
by: Bergamaschi, D, et al.
Published: (2004)

Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation.
by: Bergamaschi, D, et al.
Published: (2005)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
by: N. Daver, et al.
Published: (2022-06-01)

ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells
by: Wang, Y, et al.
Published: (2013)

ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells.
by: Wang, Y, et al.
Published: (2013)

Mutational Analysis of ASPP1 and ASPP2 Genes, a p53-related Gene, in Gastric and Cololorectal Cancers with Microsatellite Instability
Published: (2010-06-01)

AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results
by: Daver, N, et al.
Published: (2022)

Deletion of ASPP1 in myofibroblasts alleviates myocardial fibrosis by reducing p53 degradation
by: Shangxuan Li, et al.
Published: (2024-09-01)

Machine learning analysis of gene expression reveals TP53 Mutant-like AML with wild type TP53 and poor prognosis
by: Yoonkyu Lee, et al.
Published: (2024-05-01)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
by: Davidson Zhao, et al.
Published: (2023-03-01)

Essential thrombocytosis transformed AML with TP53 mutations and its clinical implications
by: Yang Si, et al.
Published: (2024-12-01)

The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP.
by: Mantovani, F, et al.
Published: (2007)

ASPP1 and ASPP2 are new transcriptional targets of E2F.
by: Fogal, V, et al.
Published: (2005)

ASPP--Apoptotic specific regulator of p53.
by: Liu, Z, et al.
Published: (2005)

P512: A PHASE 1B/2 STUDY OF TP-0903 AND DECITABINE TARGETING MUTANT TP53 AND/OR COMPLEX KARYOTYPE IN PATIENTS WITH UNTREATED ACUTE MYELOID LEUKEMIA (AML) ≥ AGE 60 YEARS: FINAL RESULTS
by: Alice Mims, et al.
Published: (2023-08-01)

TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies
by: Marianna B. Ruzinova, et al.
Published: (2019-08-01)

TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA
by: Ugo Testa, et al.
Published: (2023-06-01)

The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1.
by: Aylon, Y, et al.
Published: (2010)

P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML
by: Christian Rausch, et al.
Published: (2023-08-01)

Synthetic lethality between TP53 and ENDOD1
by: Zizhi Tang, et al.
Published: (2022-05-01)

The role of p53 and ASPP2 in neurodegenerative disease
by: Turnquist, C
Published: (2015)

P418: DELE1 LOSS AND DYSFUNCTIONAL INTEGRATED STRESS SIGNALING IN TP53 MUTATED AML IS A NOVEL PATHWAY FOR VENETOCLAX RESISTANCE
by: David Sharon, et al.
Published: (2023-08-01)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
by: Ramy Rahmé, et al.
Published: (2023-04-01)

ASPP proteins specifically stimulate the apoptotic function of p53.
by: Samuels-Lev, Y, et al.
Published: (2001)

Regulation of immunological tolerance by the p53-inhibitor iASPP
by: Akama-Garren, EH, et al.
Published: (2023)

Regulation of immunological tolerance by the p53-inhibitor iASPP
by: Elliot H. Akama-Garren, et al.
Published: (2023-02-01)

Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells
by: Jan Mueller, et al.
Published: (2024-02-01)

Variation characteristics and clinical significance of TP53 in patients with myeloid neoplasms
by: Qiang Ma, et al.
Published: (2024-12-01)

Recruiting TP53 to target chronic myeloid leukemia stem cells
by: Steven Grant
Published: (2020-05-01)

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
by: Katharina T. Prochazka, et al.
Published: (2019-03-01)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
by: Melania Tesio
Published: (2023-02-01)

Sertad1 antagonizes iASPP function by hindering its entrance into nuclei to interact with P53 in leukemic cells
by: Shaowei Qiu, et al.
Published: (2017-11-01)

Differences in Gender and Overall Survival for Temperature-Sensitive TP53 Mutations in Gastroesophageal Cancer
by: Danial H. Shaikh, et al.
Published: (2024-11-01)

TP53 Modulates Oxidative Stress in Gata1+ Erythroid Cells
by: Ashley C. Kramer, et al.
Published: (2017-02-01)

PPP and L2TP : remote access communications /
by: 338343 Black, Uyless D.
Published: (2000)

miR-106b regulates the proliferation and differentiation of neural stem/progenitor cells through Tp53inp1-Tp53-Cdkn1a axis
by: Xiaohuan Xia, et al.
Published: (2019-09-01)

Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia
by: Jun Ren, et al.
Published: (2024-06-01)